Abstract Number: 1326 • ACR Convergence 2020
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…Abstract Number: 1877 • ACR Convergence 2020
Diagnosis of Axial Spondyloarthritis: A Primary Unmet Educational Need for Rheumatologists Is Interpretation of MRI
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging because of absent physical findings in early disease and the limited diagnostic performance of laboratory markers. Considerable…Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…Abstract Number: 0904 • ACR Convergence 2020
Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks
Background/Purpose: Tumor necrosis factor inhibitors (TNFis) are effective treatments for radiographic axial spondyloarthritis (r-axSpA), but may be less effective in patients (pts) without elevated C-reactive…Abstract Number: 1327 • ACR Convergence 2020
Comorbidity Burden in Patients with Non-Radiographic Axial Spondyloarthritis at Least as High as in Ankylosing Spondylitis
Background/Purpose: Few studies have investigated the overall occurrence of comorbidities in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in relation to ankylosing spondylitis (AS). Compared to…Abstract Number: 1561 • ACR Convergence 2020
Findings Compatible with Axial Spondyloarthritis in Radiologist Reports
Background/Purpose: The sacroiliac joint (SIJ) has a distinct anatomical shape that can pose challenges to standard planar imaging techniques making the detection of subtle changes…Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…Abstract Number: 2014 • ACR Convergence 2020
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
Background/Purpose: Patients with psoriasis, iritis, or colitis and back pain represent a high-risk population for the presence of axial spondyloarthritis (axSpA). Clinicians rely on the…Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…Abstract Number: 1332 • ACR Convergence 2020
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR). AVR in AS is caused by…Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…Abstract Number: 1881 • ACR Convergence 2020
In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), spinal damage manifests as syndesmophytes and facet joint ankylosis (FJA). Whether there is an order in which lesion develops…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 67
- Next Page »
